PharmaLinea has released Prediabetiq capsules, a food supplement that aims to reduce post-meal total glucose levels, prevent peaks and crashes, and improve insulin effectiveness. These benefits have been clinically validated using real-time continuous glucose monitors. The company predicts that an increase in diabetes rates, heightened consumer awareness of glucose control, and the growing use of such monitors, particularly with the development of non-invasive glucose tracking in smartwatches by companies like Apple and Samsung, will drive demand for this product.
The majority of glucose-related food supplements currently available lack clinical data and are either commodity-based or based on basic sugar blockers, according to PharmaLinea. This makes the premium, clinically supported segment a high-growth area. With the release of Prediabetiq, the company aims to differentiate itself from competitors and offer consumers a more effective and scientifically validated solution for glycemic control.
As the incidence of diabetes continues to rise worldwide, there is a growing need for innovative products that can help manage this condition. Prediabetiq’s clinically validated benefits and use of real-time continuous glucose monitors positions it as a premium solution for those seeking improved glycemic control. PharmaLinea’s product launch reflects the company’s commitment to addressing this pressing health concern and its recognition of the potential growth in this area of the food supplement market.
